Cancer vaccines: Where are we going?

Asia-Pacific Journal of Clinical Oncology

Volumn 6, Issue SUPPL. 1, 2010, Pages

  Cebon, Jonathan ^a,b  

^a Austin Ludwig Oncology Unit   (Australia)

^b OLIVIA NEWTON JOHN CANCER RESEARCH INSTITUTE   (Australia)

Author keywords

Antigen; Cancer; Immunotherapy; Melanoma; Vaccine

Indexed keywords

CANCER VACCINE; ISCOMATRIX; MELANOMA ANTIGEN; MELANOMA ANTIGEN 3; NY ESO 1 ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ANTIGEN EXPRESSION; AUTOIMMUNITY; CANCER IMMUNOTHERAPY; DELAYED HYPERSENSITIVITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG TOLERABILITY; GENE TARGETING; HUMAN; IMMUNE RESPONSE; MELANOMA; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; TISSUE DISTRIBUTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; TUMOR REGRESSION; VACCINATION;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; TUMOR ESCAPE;

EID: 77950802427     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/j.1743-7563.2010.01270.x     Document Type: Review

References (36)

1. Gajewski TF. Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin Cancer Res 2007, 13:5256-61.
2. Ribas A, Butterfield LH, Glaspy JA, Economou JS. Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol 2003, 21:2415-32.
3. Scott AM, Cebon J. Clinical promise of tumour immunology. Lancet 1997, 349(2):SII19-22. Suppl
4. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006, 6:715-27.
5. Lizee G, Cantu MA, Hwu P. Less yin, more yang: confronting the barriers to cancer immunotherapy. Clin Cancer Res 2007, 13:5250-5.
6. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004, 21:137-48.
7. Cebon J, Gedye C, John T, Davis ID. Immunotherapy of advanced or metastatic melanoma. Clin Adv Hematol Oncol 2007, 5:994-1006.
8. Toothaker T, Rubin M. Paraneoplastic neurological syndromes: a review. Neurologist 2009, 15:21-33.
9. Oble DA, Loewe R, Yu P, Mimh MC. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. Cancer Immun 2009, 9:3.
10. Clemente CG, Mihm MC, Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996, 77:1303-10.
11. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C. Type, density, and location of immune cells within human colorectal tumours predict clinical outcome. Science 2006, 313:1960-64.
12. Davis ID, Jefford M, Parente P, Cebon J. Rational approaches to human cancer immunotherapy. J Leukoc Biol 2003, 73:3-29.
13. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human T cell responses against melanoma. Annu Rev Immunol 2006, 24:175-208.
14. Jager E, Jager D, Knuth A. Antigen-specific immunotherapy and cancer vaccines. Int J Cancer 2003, 106:817-20.
15. Kawakami Y, Eliyahu S, Sakaguchi K, Robbins PF, Rivoltini L, Yannelli JR. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci U S A 1994, 91:6458-62.
16. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Rivoltini L, Topalian SL. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A 1994, 91:3515-19.
17. Brichard V, Van Pel A, Wolfel T, Wölfel C, De Plaen E, Lethé B. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993, 178:489-95.
18. Coulie PG, Brichard V, Van Pel A, Wölfel T, Schneider J, Traversari C. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1994, 180:35-42.
19. Gaugler B, Van den Eynde B, van der Bruggen P, Romero P, Gaforio JJ, De Plaen E. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 1994, 179:921-30.
20. Boël P, Wildmann C, Sensi ML, Brasseur R, Renauld JC, Coulie P. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 1995, 2:167-75.
21. Van den Eynde B, Peeters O, De Backer O, Gaugler B, Lucas S, Boon T. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med 1995, 182:689-98.
22. Van den Eynde B, Brichard VG. New tumor antigens recognized by T cells. Curr Opin Immunol 1995, 7:674-81.
23. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991, 254:1643-7.
24. Hodi FS. Well-defined melanoma antigens as progression markers for melanoma: insights into differential expression and host response based on stage. Clin Cancer Res 2006, 12:673-8.
25. Barrow C, Browning J, MacGregor D, Davis ID, Sturrock S, Jungbluth AA. Tumor antigen expression in melanoma varies according to antigen and stage. Clin Cancer Res 2006, 12:764-71.
26. Cebon JS, Svobodova S, Browning J, Davis ID, Scolyer R, Murali R. Prognostic impact of cancer-testis antigen expression in primary cutaneous melanoma. J Clin Oncol 2009, 27:Abstract 9004.
27. Hofmann O, Caballero OL, Stevenson BJ, Chen Y-T, Cohen T, Chua R. Genome-wide analysis of cancer/testis gene expression. Proc Natl Acad Sci U S A 2008, 105:20422-7.
28. Chen Y. Identification of human tumor antigens by serological expression cloning: an online review on SEREX. Cancer Immun 2004, http://www.cancerimmunity.org/SEREX/, updated 10 Mar 2004; cited 1 Apr 2004]. Available from:
29. Jäger E, Gnjatic S, Nagata Y, Stockert E, Jäger D, Karbach J. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci U S A 2000, 97:12198-203.
30. Davis ID, Chen W, Jackson H, Parente P, Shackleton M, Hopkins W. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci U S A 2004, 101:10697-702.
31. Barr IG, Mitchell GF. ISCOMs (immunostimulating complexes): the first decade. Immunol Cell Biol 1996, 74:8-25.
32. Ennis FA, Cruz J, Jameson J, Klein M, Burt D, Thippawong J. Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS). Virology 1999, 259:256-61.
33. Kersten G, Drane D, Pearse M, Jiskoot W, Coulter A. Liposomes and ISCOMs. Novel Vaccination Strategies 2004, 173-96. Kaufmann S, In, ed., Wiley-VCH, Weinheim
34. Khong HT, Wang QJ, Rosenberg SA. Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression. J Immunother 2004, 27:184-90.
35. Nicholaou T, Ebert LM, Davis ID, McArthur GA, Jackson H, Dimopoulos N. Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma. Clin Cancer Res 2009, 15:2166-73.
36. Louahed J, Gruselle O, Gaulis S, Coche T, Eggermont AM, Kruit W. Expression of defined genes identified by pretreatment tumor profiling: association with clinical responses to the GSK MAGE- A3 immunotherapeutic in metastatic melanoma patients (EORTC 16032-18031). J Clin Oncol 2008, 26:Abstract 9045.